BrightHeart
Building on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, two leading fetal cardiologists based in Paris, France - BrightHeart is a pre-clinical medical device company developing software that leverages the power of AI to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve newborn outcomes by anticipating delivery care and early intervention.
Founded 2022
Employees 5+
Technologies Artificial Intelligence
Funding 💰
Key people 🧑🤝🧑
- Marilyne Levy, MD - Co-founder
- Bertrand Stos, MD - Co-founder
- Cécile Dupont Redon - CEO
- Christophe Gardella, PhD - CTO
Highlights ⭐
- Solving the problem: Prenatal diagnosis of fetal heart defects can significantly improve newborn outcomes, but in practice, as few as 30% are detected. BrightHeart's AI-powered approach has the potential to revolutionize screening for congenital heart defects by supporting clinicians with a real-time, expert-level interpretation of one of the most complex exams in the ultrasound practice.
- Database access: Beyond expertise, BrightHeart's founders bring a proprietary database of more than 20,000 fetal ultrasound exams to the company. This database, combined with the company's AI technology, can help caregivers improve the detection of complex fetal heart defects in utero, during an ultrasound screening exam, when early interventions could either correct them or greatly improve a child's chance of survival.
- Solid team: BrightHeart has brought together an experienced team in the fields of fetal cardiology, AI, and software development. This group is led by CTO Christophe Gardella, an accomplished data scientist and leader with extensive experience in the development of AI-powered MedTech solutions who directed the algorithm efforts at Cardiologs.
Last update: June 28, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more